Dyadic receives $4.5M CEPI grant for C1 fungus-based vaccine development

DYADIC INTERNATIONAL INC

CEPI awards $4.5M to non-profit FBS for proof-of-concept using Dyadic's C1 fungus to produce vaccine antigens.
Goal: reduce vaccine production and release time to 35 days, versus 4-6 months for mammalian cell lines.
Project will compare SARS-CoV-2 spike protein produced in C1 vs. mammalian cells for structure and immunogenicity.
Technology aims to enable faster, scalable, and affordable vaccine manufacturing for pandemic response (100 Days Mission).
Dyadic's CEO notes support for global health security and One Health approach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.